Cavariani, Marilia Martins [UNESP]de Almeida Kiguti, Luiz Ricardo [UNESP]de Lima Rosa, Josiane [UNESP]de Araújo Leite, Gabriel Adan [UNESP]Silva, Patrícia Villela E [UNESP]Pupo, André Sampaio [UNESP]De Grava Kempinas, Wilma [UNESP]2015-12-072015-12-072015Journal Of Applied Toxicology : Jat, v. 35, n. 9, p. 1007-1016, 2015.1099-1263http://hdl.handle.net/11449/131242Bupropion is a dopamine (DA) and norepinephrine (NE) reuptake inhibitor used as smoking cessation and antidepressant drug with a lower incidence of male sexual dysfunction. We showed previously that sibutramine, a norepinephrine/serotonine reuptake inhibitor, reduced male rat fertility. As there are no studies evaluating the impact of bupropion treatment on spermatic parameters and male fertility, we evaluated the effects of bupropion treatment (15 and 30 mg kg(-1), 30 days) on sexual behavior, spermatic parameters and fertility of male Wistar rats and on the epididymal duct in vitro contractility. Bupropion 15 mg kg(-1) increased the serum luteinizing hormone level and the epididymal duct contractility, but the sperm quality was not affected. At 30 mg kg(-1) bupropion impaired sperm quality increasing the incidence of non-progressive sperm. The male sexual behavior and fertility were not modified at both bupropion doses. These results, in rats, suggest the importance of studies evaluating the effects of bupropion on the human male sperm quality.1007-1016engBupropionEpididymal contractionNorepinephrine transporterSperm qualitySperm transit timeArtigo10.1002/jat.3089Acesso restrito2224433126054725632645027116974125645087